



# STRATEGEM CAPITAL

*Strength Through Strategy*

## **STRATEGEM CAPITAL CORPORATION**

### **CONDENSED INTERIM FINANCIAL STATEMENTS**

**FOR THE THREE MONTHS ENDED MARCH 31, 2022**

#### **NOTICE OF NO AUDITOR'S REVIEW OF INTERIM FINANCIAL STATEMENTS**

The accompanying unaudited condensed interim financial statements of Strategem Capital Corporation (the "Company") have been prepared by the management and approved by the Company's Audit & Corporate Governance Committee and by the Company's Board of Directors.

The accompanying unaudited condensed interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

**The Company's independent auditor has not performed a review of these unaudited condensed interim financial statements.**

**STRATEGEM CAPITAL CORPORATION**  
**CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION**  
(EXPRESSED IN THOUSANDS OF CANADIAN DOLLARS)  
(UNAUDITED)

	Notes	March 31, 2022	December 31, 2021
<b>ASSETS</b>			
<b>Current assets</b>			
Cash and cash equivalents		\$ 3,038	\$ 2,122
Accounts receivable		60	38
Short-term investments	<b>6</b>	23,344	30,958
<b>Total current assets</b>		26,442	33,118
<b>TOTAL ASSETS</b>		\$ 26,442	\$ 33,118
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Accounts payable and accrued liabilities		\$ 36	\$ 36
Due to related parties	<b>9</b>	9	900
<b>Total current liabilities</b>		45	936
<b>Non-current liabilities</b>			
Deferred income tax liability		1,197	2,725
<b>Total non-current liabilities</b>		1,197	2,725
<b>TOTAL LIABILITIES</b>		\$ 1,242	\$ 3,661
<b>EQUITY</b>			
Share capital	<b>7</b>	11,681	11,826
Retained earnings		13,519	17,631
<b>Total equity</b>		25,200	29,457
<b>TOTAL EQUITY AND LIABILITIES</b>		\$ 26,442	\$ 33,118

These financial statements were authorized for issue by the Board of Directors on May 26, 2022.

These financial statements are signed on the Company's behalf by:

(signed) "Hon. Stockwell Day"  
Director

(signed) "Desmond Balakrishnan"  
Director

**STRATEGEM CAPITAL CORPORATION**  
**CONDENSED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**  
(EXPRESSED IN THOUSANDS OF CANADIAN DOLLARS, EXCEPT PER SHARE DATA)  
(UNAUDITED)

		Three months ended March 31,	
	Notes	2022	2021
<b>Revenues</b>			
Interest, dividends and other income		\$ 170	\$ 28
Net gain on sale of investments		108	5
Net unrealized gain (loss) on investments		(5,672)	7,715
<b>Total revenues</b>		<b>(5,394)</b>	<b>7,748</b>
<b>Expenses</b>			
Management fees	9	66	290
Salaries	9	80	-
Director and committee fees	9	63	13
Professional fees	9	14	17
Office and general		10	4
Shareholder information and filing fees		4	9
Commission expense	9	5	11
<b>Total expenses</b>		<b>242</b>	<b>344</b>
<b>Other items</b>			
Foreign exchange loss		(4)	(3)
<b>Income before income taxes</b>		<b>(5,640)</b>	<b>7,401</b>
Deferred income tax recovery		1,528	-
<b>Net income (loss) and comprehensive income (loss) for the period</b>		<b>\$ (4,112)</b>	<b>\$ 7,401</b>
<b>Earnings (loss) per share - basic and diluted</b>	<b>8</b>	<b>\$ (0.44)</b>	<b>\$ 1.74</b>

**STRATEGEM CAPITAL CORPORATION**  
**CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY**  
(EXPRESSED IN THOUSANDS OF CANADIAN DOLLARS)  
UNAUDITED

	Class A Number of Shares	Class A Share Capital	Class B Number of Shares	Class B Share Capital	Retained Earnings	Total Equity
Issued and outstanding						
<b>Balance as at January 1, 2021</b>	4,245,699	\$ -	220	\$ 1	\$ 9,348	\$ 9,349
Net income for the period	-	-	-	-	7,401	7,401
<b>Balance as at March 31, 2021</b>	4,245,699	-	220	1	16,749	16,750
Net loss for the period	-	-	-	-	882	882
Private Placement	5,191,229	11,825	-	-	-	11,825
<b>Balance as at December 31, 2021</b>	9,436,928	11,825	220	1	17,631	29,457
Net income for the period	-	-	-	-	(4,112)	(4,112)
Normal course issuer bid	(58,400)	\$ (145)	-	-	-	(145)
<b>Balance as at March 31, 2022</b>	9,378,528	\$ 11,680	220	\$ 1	\$ 13,519	\$ 25,200

**STRATEGEM CAPITAL CORPORATION**  
**CONDENSED INTERIM STATEMENTS OF CASH FLOWS**  
(EXPRESSED IN THOUSANDS OF CANADIAN DOLLARS)  
UNAUDITED

	<b>For the three months ended</b>	
	<b>March 31,</b>	
	<b>2022</b>	<b>2021</b>
<b>Cash flow from operating activities</b>		
Net income	\$ (4,112)	\$ 7,401
Adjustments to reconcile to net cash flows from operating activities:		
Gain on sale of investments	(108)	(5)
Unrealized gain on investments	5,672	(7,715)
Foreign exchange loss (gain)	4	(1)
Deferred income tax recovery	(1,528)	-
	(72)	(320)
Changes in non-cash working capital items:		
Accounts receivable	(22)	-
Accounts payable and accrued liabilities	-	22
Due to related parties	(891)	243
	(913)	265
Changes in other items:		
Proceeds from sale of investments	2,091	2,802
Purchase of investments	(45)	(6,675)
	2,046	(3,873)
<b>Net cash provided by (used in) operating activities</b>	<b>1,061</b>	<b>(3,929)</b>
<b>Cash flow from financing activities</b>		
Normal course issuer bid	(145)	-
<b>Net cash used in financing activities</b>	<b>(145)</b>	<b>-</b>
<b>Net change in cash and cash equivalents</b>	<b>916</b>	<b>(3,929)</b>
<b>Cash and cash equivalents, beginning of the period</b>	<b>2,122</b>	<b>4,773</b>
<b>Cash and cash equivalents, end of the period</b>	<b>\$ 3,038</b>	<b>\$ 844</b>
<b>Supplemental cash flow information</b>		
Dividends received	\$ 148	\$ 27
Interest received	\$ -	\$ 1

**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS  
FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021**  
(EXPRESSED IN THOUSANDS OF CANADIAN DOLLARS, EXCEPT PER SHARE DATA)  
(UNAUDITED)

---

**1. Nature of operations and continuance of operations**

Strategem Capital Corporation (the “Company” or “Strategem”) invests in resource exploration and development opportunities, mining, energy production and agricultural protein products and is listed on the TSX Venture Exchange (the “TSX-V” or the “Exchange”). The Company’s objective since inception in December 1994 is to own and manage operating businesses. The Company’s head office is: Suite 210, 240 11 Avenue SW, Calgary, Alberta, Canada, T2R 0C3. The Company’s Class A shares trade under the symbol “SGE” on the TSX Venture Exchange.

These condensed interim financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) applicable to a going concern, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. During the three months ended March 31, 2022, the Company reported net loss of \$4,112 (March 31, 2021 - net income of \$7,401). As at March 31, 2022, the Company had cash and cash equivalents of \$3,038 (December 31, 2021 - \$2,122) and working capital of \$26,397 (December 31, 2021 - \$32,182).

**2. Basis of preparation**

These condensed interim financial statements are prepared in accordance with IFRS, including International Accounting Standard (“IAS”) 34 Interim Financial Reporting, as issued by the IASB. These condensed interim financial statements should be read in conjunction with the annual financial statements for the year ended December 31, 2021, which have been prepared in accordance with IFRS and include information necessary or useful to understanding the Company’s business and financial statement presentation.

These financial statements have been prepared on a historical cost basis (other than investments which are valued using fair value basis). In addition, these financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

The preparation of financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates.

These financial statements, including comparatives, have been prepared on the basis of IFRS standards that are published at the time of preparation.

**3. Significant accounting policies**

The accounting policies applied in these condensed interim financial statements are consistent with those applied in the preparation of the Company’s annual financial statements, except for the addition of the accounting policies related to share capital as included below. These condensed interim financial statements should be read in conjunction with the annual financial statements for the year ended December 31, 2021. Areas of judgement that have the most significant effect on the amounts recognized in the interim financial statements are disclosed in Note 3(a) of the Company’s financial statements for the year ended December 31, 2021. There have been no significant changes to the areas of estimation and judgement during the three months ended March 31, 2022.

In the opinion of management, all adjustments considered necessary for fair presentation of the Company’s financial position, results of operations and cash flows have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.

**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS  
FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021**  
(EXPRESSED IN THOUSANDS OF CANADIAN DOLLARS, EXCEPT PER SHARE DATA)  
(UNAUDITED)

**4. Management of capital**

The Company manages its common shares, stock options and warrants as capital. The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to pursue suitable equity investments and to maintain a flexible capital structure which optimizes the costs of capital at an acceptable risk.

The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares, issue new debt, acquire or dispose of assets or adjust the amount of cash and cash equivalents. The Company does not have any externally imposed capital requirements.

**5. Financial risk factors**

In the normal course of business, the Company's activities expose it to a variety of financial risks that may affect its operating performance. These risks are credit risk and market risk (including interest rate risk, currency risk and other price risk). The level of risk to which the Company is exposed depends on the type of investments the Company holds. The value of investments can fluctuate daily as a result of changes in prevailing interest rates, economic and market conditions and company specific news.

These condensed interim financial statements do not include all financial risk management information and disclosures required in the annual financial statements. These statements should be read in conjunction with the annual financial statements as at December 31, 2021. There have been no changes in the risk management or any risk management policies since year end.

**6. Short-term Investments**

The Company held the following short-term investments as at March 31, 2022:

	<b>Cost</b>	<b>Fair Market Value</b>
Public company securities	\$ 17,823	\$ 23,035
Private company	302	309
<b>Total Investments</b>	<b>\$ 18,125</b>	<b>\$ 23,344</b>

The Company held the following short-term investments as at December 31, 2021:

	<b>Cost</b>	<b>Fair Market Value</b>
Public company securities	\$ 19,621	\$ 30,645
Private company	302	313
<b>Total Investments</b>	<b>\$ 19,923</b>	<b>\$ 30,958</b>

Short-term investments are held for trading and are classified as Level 1 Financial Instruments.

**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS  
FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021**  
(EXPRESSED IN THOUSANDS OF CANADIAN DOLLARS, EXCEPT PER SHARE DATA)  
(UNAUDITED)

**7. Share capital**

**(a) Authorized:**

- Unlimited Class A voting common shares without par value;
- Unlimited Class B voting common shares without par value;
- Unlimited Class A non-voting preference shares without par value.

**(b) Issued and outstanding**

<b>Class A Shares</b>	<b>Number of Shares</b>	<b>Value</b>
Balance, December 31, 2021	9,436,928	\$ 11,825
Normal Course Issuer Bid	(58,400)	(145)
<b>Balance, March 31, 2022</b>	<b>9,378,528</b>	<b>\$ 11,680</b>

<b>Class B Shares</b>	<b>Number of Shares</b>	<b>Value</b>
<b>Balance, December 31, 2021 and March 31, 2022</b>	<b>220</b>	<b>\$ 1</b>

As at March 31, 2022, the Company had 9,378,528 Class A common shares and 220 Class B common shares issued and outstanding. Each Class B common share can be exchanged for one Class A common share. Upon exchange, the Class B voting common shares will be cancelled by the Company.

**(c) Warrants**

The Company's Warrants as at March 31, 2022 are:

	<b>Number of Warrants</b>	<b>Weighted-Average Exercise Price</b>
<b>Balance, March 31, 2022 and December 31, 2021</b>	<b>5,191,229</b>	<b>\$ 2.75</b>

Each Warrant entitles the holder to purchase one common share of the Company at a price of \$2.75 per share on or before May 17, 2024. If at any time the closing price of the Company's Share is equal to or greater than \$10.00 per share for a period of 15 consecutive trading days, the Company may accelerate the expiry date of the Warrants by giving notice to the holders and in such case, the Warrants will expire on the 30<sup>th</sup> business day after the date on which notice is given by the Company in accordance with its terms.

**(d) Normal Course Issuer Bid**

On September 20, 2021, the Company obtained an approval from the Exchange to undertake a Normal Course Issuer Bid to allow the Company to purchase up to 471,846 of its Class A common shares, representing approximately 5% of its issued and outstanding shares. Purchases may be made on the open market through the facilities of the Exchange by the designated broker until September 19, 2022.

During the three months ended March 31, 2022, 58,400 Class A common shares were purchased for \$145 under the Normal Course Issuer Bid. These common shares were returned to treasury and cancelled.

**(e) Stock options**

There were no options outstanding as of March 31, 2022 and December 31, 2021.



**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS  
FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021**  
(EXPRESSED IN THOUSANDS OF CANADIAN DOLLARS, EXCEPT PER SHARE DATA)  
(UNAUDITED)

**8. Earnings (loss) per share**

	Three months ended March 31,	
	2022	2021
Income (loss) attributable to common shareholders	\$ (4,112)	\$ 7,401
Weighted average shares outstanding - basic and diluted	9,359	4,246
Earnings (loss) per share - basic and diluted	\$ (0.44)	\$ 1.74

**9. Management compensation and related party expenses**

	Three months ended March 31,	
	2022	2021
Management fees	\$ 66	\$ 290
Salaries	80	-
Director fee & committee fees	63	13
Legal fees	9	17
Commission expense	5	-
	\$ 223	\$ 320

At March 31, 2022, management includes five directors and three members of the management executive team (December 31, 2021 - five directors and three members of the management executive team). For the three months ended March 31, 2022, three of the five directors waived their director fees. One director is a partner of McMillan LLP, a firm which provides legal services to the Company. For the three months ended March 31, 2022, legal fees paid to a related party were \$9. One director is a senior managing director of Canaccord Genuity Wealth Management. For the three months ended March 31, 2022, commission paid to a related party were \$5.

At March 31, 2022, \$9 payable to McMillan LLP and \$nil payable to the executive management team were included in due to related parties (at December 31, 2021 - \$20 payable to McMillan LLP, \$880 payable to the executive team).

**10. Comparative amounts**

Certain comparative amounts for the prior period have been reclassified to conform to the current period presentation. Such reclassification has no effect on net income or shareholder's equity.



# STRATEGEM CAPITAL

*Strength Through Strategy*

## **Board of Directors**

Honourable Stockwell Day, Chairman  
Desmond Balakrishnan  
Matthew Cicci, CFA  
Gordon Flatt  
Dickson Gould

## **Executive Officers**

Jo-Anne O'Connor, President & Chief Executive Officer  
Carol Fozo, CPA, CMA, Chief Financial Officer and Secretary  
Gordon Flatt, Managing Partner & Chief Investment Strategist  
Dr. John Waterer, Chief Science Officer & Director of Life Science

## **Legal**

McMillan LLP

## **Auditor**

DeVisser Gray LLP, Chartered Professional Accountants  
Vancouver, British Columbia, Canada

## **Committees**

*Audit & Corporate Governance Committee*  
Desmond Balakrishnan, Chairman  
Matthew Cicci  
Honourable Stockwell Day

*Office of the President*  
Gordon Flatt, Chairman  
Jo-Anne O'Connor

*Science and Technology Advisory Committee (STAC)*  
Graydon Flatt, Chairman  
Dr. John Waterer, PhD  
Gordon Flatt

*Global Investment Advisory Committee (GIAC)*<sup>1</sup>  
Honourable Stockwell Day – Canada  
Gordon Flatt – Bermuda  
Angelina Ho – Hong Kong  
William Molson – USA / Canada  
Lars Rodert – Sweden  
Pablo Vizcaino – Argentina

---

<sup>1</sup> Countries of residency